Vizgen
Top Five Articles on GenomeWeb Last Week: Illumina, Fore Genomics, Inocras, Roche, More
Last week, GenomeWeb's readers were most interested in Illumina potentially facing sanctions after being placed on China's "unreliable entities" list.
Vizgen has alleged that Harvard renegotiated its license to ReadCoor in 2020, putting it on a "collision course" with Vizgen.
In Brief This Week: Natera, Enzo Biochem, Tempus, Vizgen, Complete Genomics, Parse Biosciences, More
News items for the week of Dec. 16, 2024.
The past year was difficult for many life science tools companies but not all doom and gloom for some single-cell and spatial omics firms.
Vizgen to Merge With Ultivue, Announces Series D Financing
The deal follows a March restructuring for Harvard University spinout Vizgen, which followed a round of layoffs in October 2023.